Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Daniel R. Getts, Meghann T. Getts, Derrick P. McCarthy, Emily ML Chastain & Stephen D. Miller. (2010) Have we overestimated the benefit of human(ized) antibodies?. mAbs 2:6, pages 682-694.
Read now
Read now
Peter J Bugelski, Ram Achuthanandam, Renold J Capocasale, George Treacy & Esther Bouman-Thio. (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Review of Clinical Immunology 5:5, pages 499-521.
Read now
Read now
Articles from other publishers (19)
Lei Yang, Nigora Atakhanova, Meryelem Tania Churampi Arellano, Mohammed Yassen Mohamed, Thamer Hani, Ali A. Fahdil, Roxana Yolanda Castillo-Acobo, Ashima Juyal, Ahlam Kadhim Hussein, Ali H. Amin, Renzon Daniel Cosme Pecho & Reza Akhavan-Sigari. (2023) Translational research of new developments in targeted therapy of colorectal cancer. Pathology - Research and Practice 252, pages 154888.
Crossref
Crossref
Faezeh Sharafi, Sadegh Abaei Hasani, Samira Alesaeidi, Mohammad Saeed Kahrizi, Ali Adili, Shadi Ghoreishizadeh, Navid Shomali, Rozita Tamjidifar, Ramin Aslaminabad & Morteza Akbari. (2022) A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review. Cancer Cell International 22:1.
Crossref
Crossref
Andriani Charalambous & Mark-Alexander Schwarzbich. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
42
.
Shima Makaremi, Zahra Asadzadeh, Nima Hemmat, Amir Baghbanzadeh, Alessandro Sgambato, Farid Ghorbaninezhad, Hossein Safarpour, Antonella Argentiero, Oronzo Brunetti, Renato Bernardini, Nicola Silvestris & Behzad Baradaran. (2021) Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 9:9, pages 1075.
Crossref
Crossref
Marc Armengol, Juliana Carvalho Santos, Miranda Fernández-Serrano, Núria Profitós-Pelejà, Marcelo Lima Ribeiro & Gaël Roué. (2021) Immune-Checkpoint Inhibitors in B-Cell Lymphoma. Cancers 13:2, pages 214.
Crossref
Crossref
Sima Rahimian, Marieke F. Fransen, Jan Willem Kleinovink, Maryam Amidi, Ferry Ossendorp & Wim E. Hennink. (2015) Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials 61, pages 33-40.
Crossref
Crossref
Luis H. Camacho. (2015)
CTLA
‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
. Cancer Medicine 4:5, pages 661-672.
Crossref
Crossref
Erjian Wang, Dongwoo Kang, Kyun-Seop Bae, Margaret A. Marshall, Dmitri Pavlov & Kourosh Parivar. (2014) Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. The Journal of Clinical Pharmacology 54:10, pages 1108-1116.
Crossref
Crossref
L. Guilleminault, E. Lemarié & N. Heuzé-Vourc’h. (2012) Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer. Journal of Cancer Therapy 03:06, pages 1170-1190.
Crossref
Crossref
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 26:1, pages 1-64.
Crossref
Crossref
Tabasum Sidiq, Anamika Khajuria, Pankaj Suden, Rohit Sharma, Surjeet Singh, K.A. Suri, N.K. Satti & R.K. Johri. (2011) Possible role of macrophages induced by an irridoid glycoside (RLJ-NE-299A) in host defense mechanism. International Immunopharmacology 11:1, pages 128-135.
Crossref
Crossref
Sandy Azzi, Vincent Parissi, Richard G. Maroun, Pierre Eid, Olivier Mauffret & Serge Fermandjian. (2010) The HIV-1 Integrase ?4-Helix Involved in LTR-DNA Recognition Is also a Highly Antigenic Peptide Element. PLoS ONE 5:12, pages e16001.
Crossref
Crossref
Sanjiv S. Agarwala & Antoni Ribas. (2010) Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors. Journal of Immunotherapy 33:6, pages 557-569.
Crossref
Crossref
Antoni Ribas, Matthias R. Benz, Martin S. Allen-Auerbach, Caius Radu, Bartosz Chmielowski, Elizabeth Seja, John L. Williams, Jesus Gomez-Navarro, Timothy McCarthy & Johannes Czernin. (2010)
Imaging of CTLA4 Blockade–Induced Cell Replication with
18
F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
. Journal of Nuclear Medicine 51:3, pages 340-346.
Crossref
Crossref
Caroline Robert & Francois Ghiringhelli. (2009) What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?. The Oncologist 14:8, pages 848-861.
Crossref
Crossref
Luis H. CamachoScott AntoniaJeffrey SosmanJohn M. KirkwoodThomas F. GajewskiBruce RedmanDmitri PavlovCecile BulanhaguiViviana A. BozonJesus Gomez-NavarroAntoni Ribas. (2009) Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology 27:7, pages 1075-1081.
Crossref
Crossref
Robert O. Dillman. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy
303
406
.
Nils Lonberg. (2008) Fully human antibodies from transgenic mouse and phage display platforms. Current Opinion in Immunology 20:4, pages 450-459.
Crossref
Crossref
DE Heron, JE Shogan & JW Mucenski. (2008) Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim. Biomedical Imaging and Intervention Journal 4:3.
Crossref
Crossref